Abstract
Abstract
Background
Dapoxetine hydrochloride is a selective serotonin reuptake inhibitor drug for treating premature ejaculation. This study was designed to develop and validate a sensitive and selective LC–MS/MS method for trace analysis of genotoxic impurity ethyl methanesulfonate in Dapoxetine hydrochloride.
Results
Chromatographic separation was achieved on the Shodex RSpak DS-413 column, 150 × 4.6 mm, 3.0 µm using eluent containing a equal volumes of acetonitrile and 0.1% v/v formic acid in water was used in the isocratic elution mode at a pump flow of 1.0 mL/min. No interference was observed at the retention time of ethyl methanesulfonate, indicating that the developed method is specific and selective for trace level quantification.The developed method was found to be linear in the concentration range of 1–50 ppm with coefficient of regression of 0.9997. Detection limit and quantification limit were determined to be 0.6 ppm and 1.0 ppm respectively. Acceptable RSD values (< 10.0%) and recovery results (> 90%) obtained from the accuracy and precison experiments indicate that the developed method is precise and accurate in the concentration range of 1–50 ppm. Ethyl methanesulfonate solutions were stable for two days when stored at room and refrigerated temperatures.
Conclusion
The developed method has the ability to quantify ethyl methanesulfonate in dapoxetine hydrochloride. Thus, the anticipated method has high probability to adopt in the quality testing laboratories of pharmaceutical industry.
Publisher
Springer Science and Business Media LLC
Reference21 articles.
1. ICH Q3A (R2) (2006) Impurities in new drug substances. https://database.ich.org/sites/default/files/Q3A_R2__Guideline.pdf. Accessed 26 May 2021
2. ICH M7 Guideline (2017) Assessment and control of DNA reactive (Mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk. https://database.ich.org/sites/default/files/M7_R1_Guideline.pdf. Accessed 26 May 2021
3. Nishit Modi B, Mark JD, Mary S, Denise L, Dhaval D, Suneel G (2006) Single- and multiple-dose pharmacokinetics of dapoxetine hydrochloride, a novel agent for the treatment of premature ejaculation. J Clin Pharmacol 46:301–309
4. Muller L, Mauthe RJ, Riley CM, Andino MM, Antonis DD, Beels C, De George D, De Knaep AGM, Ellison D, Fagerland JA, Frank R, Fritschel B, Galloway S, Harpur E, Humfrey CDN, Jacks AS, Jagota N, Mackinnon J, Mohan G, Ness DK, Donovan MRO, Smith MD, Vudathala G, Yotti L (2006) A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity. Regul Toxi Pharm 44:198–211
5. Snodin DJ (2010) Genotoxic impurities: from structural alerts to qualification. Org Process Res Dev 14:960–976